Cardiovascular DiseasesBASHNCT01929564
Broccoli and Vascular Health Study
A study testing Beneforte broccoli and Parthenon Broccoli in people with Cardiovascular Diseases, run by Quadram Institute Bioscience at 2 sites in United Kingdom.
Trial summary
The participants of this study will be men \& women ≥50 years who are deemed to have a 10-30% risk of developing CVD over the next 10 years. Their risk will be calculated using the Joint British Societies 2 (JBS2) guidelines on the prevention of CVD in clinical practise algorithm. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases
- What is being tested?
- Beneforte broccoli and Parthenon Broccoli
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 95 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- Jul 2012to May 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men and women aged ≥ 50 years will be recruited onto the study using the JBS 2 cardiac risk assessor calculator.
- Scores of 10%-30% will be acceptable for participation in the study.
Who cannot join
- Those unable to give written informed consent
- Those unwilling to provide GP details
- Those already consuming Beneforté ® broccoli, unless they are willing to discontinue consumption for 8 weeks prior to starting the study.
- Diagnosed diabetics
- Fasting glucose >7mmol/L (WHO guidelines for diabetics)
- Blood pressure <90/50 or 95/55 if symptomatic; >160/100
Show all 35Show fewer
- Chronic kidney disease
- BMI <20
- BMI >40
- Fasting total cholesterol > 8.0mmol/L
- Fasting glucose >7mmol/L (WHO guidelines for diabetics)
- Blood pressure <90/50 or 95/55 if symptomatic; >160/100
- Chronic kidney disease
- BMI <20
- BMI >40
- Fasting total cholesterol > 8.0mmol/L
- Haemoglobin Men <13.8g/dL (8.56mmol/L) Women <12.1g/DL (<5.51mmol/L)
- Peri-menopausal women (defined as : when there is a change in menses)
- Women on HRT for less than one year
- Women who are pregnant or breastfeeding
- Those taking self-prescribed aspirin for cardiovascular reasons
- All those taking blood pressure medication
- Those on any lipid lowering therapies such as statins, bile acid sequestrants, cholesterol absorption inhibitors and nicotinic acid
- Those on regular medication for hypercoagulation and inflammatory conditions e.g. corticosteroids and asthma (intermittent use of an inhaler will be discussed on an individual basis)
- Those on glucose lowering medications
- Those who have ever suffered a cardiovascular event such as stroke, myocardial infarction or trans ischemic attacks
- Peripheral vascular disease including Claudication
- Consumption of fish oil supplements (unless participant is willing to discontinue their use 8 weeks prior to the start of the intervention- all other supplements with be dealt with on an individual basis)
- Parallel participation in another research project which involves dietary intervention and/or sampling of blood
- Any person related to or living with any member of the study team
- Participation in another research project which involves blood sampling within the last four months unless the total blood from both studies (including this one) does not exceed 470mL)
- Those who have donated or intend to donate blood within 16 weeks of the first and last study samples
- Gastrointestinal disease (excluding hiatus hernia) unless symptomatic or study intervention/procedure is contraindicated
- Going on holiday for more than two weeks during the intervention
- Those undergoing any on-going GP investigation
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Institute of Food Research
Norwich, Norfolk, NR4 7UA
University of Reading
Reading, Berkshire, RG6 6AH
About this study
The participants of this study will be men \& women ≥50 years who are deemed to have a 10-30% risk of developing CVD over the next 10 years. Their risk will be calculated using the Joint British Societies 2 (JBS2) guidelines on the prevention of CVD in clinical practise algorithm. This takes into account the participants age, sex, cholesterol values, blood pressure,family history and their ethnicity (SE Asian or not). The participants will be randomly assigned to one of two groups with the aid of a computer program called "minim" which uses their age, sex, BMI and smoking status to determine which broccoli each participant will consume on the intervention.
Each participant will consume 4 x 100g of their assigned broccoli, each week for 12 weeks on top of their normal diet. They will be allowed to eat the broccoli whenever they want during the week, but will be asked to note down when they eat it. A steamer will be provided so participants can cook their broccoli for the required 4-5 minutes. Participants will be asked to keep two diet diaries during their time on the intervention, one before they start the intervention and one towards the end. Blood samples and urine will also be collected, pre and post intervention, for the analysis of biomarkers of CVD.
This is joint project based at two sites, the Institute of Food (IFR) Research in Norwich and the University of Reading(UoR), in Reading. Samples from the participants at both sites will be analysed at IFR, UoR and companies in the United States.
Read the detailed description
This intervention will take place at two independent sites, The Institute of Food Research's Human Nutrition Unit (HNU)in Norwich and the Hugh Sinclair Human Nutrition Unit (HSU), at the University of Reading. The participants recruited from Norwich and Reading will solely attend the unit in their area and the paper work has been written to reflect this i.e.separate participant information sheets (PIS). In addition to the tests carried out at both sites, the Reading cohort will also undergo additional vascular tests, also reflected in the PIS. Despite the sites being independent, 96 participants will be recruited across both sites, with the possibility of uneven numbers from each site making up the final number.
The purpose of this study is to assess whether diet can affect an individuals chances of developing CVD, as it is one of the biggest killers in the UK. We are particularly interested in participants who have a 10%-30% risk of developing CVD. We are able to assess a person's risk with the help of the Joint British Societies 2 guidelines on the prevention of cardiovascular disease, cardiovascular disease risk prediction chart. These charts take a number of parameters we obtain from the participant, their age, sex, total cholesterol concentration, systolic blood pressure (BP), body mass index (BMI), serum high density lipoprotein concentration, their smoking status and diabetes status and put them into an algorithm. The result is a risk score out of 100, of a person developing CVD over the next 10 years.
The study will be conducted over two sites, Reading and Norwich, with a principal investigator assigned to each site. The total number of participants recruited over both sites will be 96. It may be that uneven numbers are recruited over the two sites e.g. 46 at one and 50 at another however regardless of the number at each site, 48 participants will be assigned to each of the two groups. One group will consume 400g of the commercially available high glucosinolate Beneforté® broccoli each week for 12 weeks and the other will consume 400g of a standard broccoli, Parthenon for 12 weeks.
As we are assessing the effect of diet on CVD risk, our participants will be screened initially. Their urine will be tested (urine dipstick test), their height, weight, waist and hip measurements, BMI, BP will be measured and questions linked to lifestyle choices (alcohol consumption, smoking status and physical activity) will be asked. A separate section pertaining to women's health will also be present on the questionnaire.
All participants will be asked to give written informed consent before they can participate in the intervention study. The Reading cohort will be sent a copy of the consent and medical declaration forms to read through at home. The forms sent to the homes will be clearly distinguishable from the real forms as they will have the watermark with "SAMPLE" written across them.
CVD risk assessment calculator This calculator will be used once the results of the screening are known. A program devised by the University of Manchester will be used to calculate the risk our participants have of developing CVD over the next 10 years. This program is based on the Joint British Societies 2 guidelines on the prevention of CVD risk prediction charts. For the purposes of this study we would like our participants to fall into the 10%-30% risk category as most literature suggests people in this range may benefit from dietary change, without the need for medication, in the most part. The CVD risk scores will be sent to the participants GP and we will continue to advise our participants to discuss the results with their GPs if they score >10%.
Genotyping There is evidence to suggest that a person's genetic make-up may affect the way isothiocyanates (ITCs), one of the active components of broccoli, work. Of the 30,000 genes found in humans a group of genes associated with the protein glutathione S-transferase M1 (GSTM1) has been shown to affect ITCs after consumption and has been implicated in CVD. There is evidence to suggest that individuals with a deletion in GSTM1 breakdown the glucosinolate, from which the ITC sulforaphane is derived, differently to individuals that have the gene. We also know that glutathione S-transferase theta-1 (GSTT1) may also be involved in reducing the likelihood of developing CVD.
Along with the GST gene family and their association with cruciferous vegetables, there are a number of other genes that have been implicated in CVD itself. These include genes associated with lipid metabolism, thrombosis, leukocyte adhesion and nitric oxide production and thus blood vessel dilation. This is by no means an exhaustive list and will therefore remain open to other viable candidates.
Vascular measurements As we age, our arteries stiffen which causes an increase in the demands of the heart and an increase in blood pressure. This increase in BP can dramatically increase the risk of heart attack, stroke and heart failure. Arterial stiffness has also been associated with many of the common risk factors associated with CVD such as age, high blood pressure, smoking, cholesterol levels and obesity, but importantly, arterial stiffness has been shown to be an independent predictor of CVD in a large section of society.
There are many ways in which arterial stiffness can be assessed. We will be looking at blood pressure, which will be very familiar to most participants in our age range (over 50yrs of age). The only difference being that the participant will wear a cuff for an hour and readings will be collected every ten minutes.
Another method will be Pulse Wave Analysis (PWA), where a probe will be held against the neck and the upper thigh to take the measurements for up to a minute at a time. As participants may not be wholly familiar with this technique, it is hoped that a short video clip could be shown on a laptop or diagrams/photographs of the technique will be discussed with the participant at screening.
Restricted conditions prior to study day Before the study day the participants will be asked to abstain from a number of activities. This will be clearly stated in the PIS.
These include:
- No alcohol or caffeine for 24 hours before the study day. Participants who consume a lot of caffeine will be advised that they may suffer from headaches. They will be asked to tell the study scientist if they needed to take any medication as a consequence.
- Low fat meal to be consumed the night before the study day. Participants will be asked to eat a low fat meal from a selected list that we give them. We will ask that the meal is consumed before 10pm, as the participants will then have to fast for their study day.
- Fasting for at least 8 hours. Participants will need to fast for at least 8 hours. This means that they won't be able to eat or drink anything, apart from water during this time. They can drink as much water as they feel they need.
- No heavy exercise the morning of their study day. Participants will be asked not to engage in any vigorous exercise the morning of their study day. This will be defined as any activity that causes an increase in heart rate, panting and/or sweating. A participant who normally cycles will be asked not to on the morning of their study day.
- No smoking an hour before their study day measurements. All participants that smoke will be asked to abstain from smoking at least an hour before their study day. We would also ask that they avoid all passive smoking.
- Conditions
- Cardiovascular Diseases
- Being tested
- Beneforte broccoli, Parthenon Broccoli
- Keywords
- cardiovascular disease, risk factor, broccoli, GST, blood pressure, Total cholesterol
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beneforte broccoliOther
Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
Parthenon BroccoliOther
Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
| Study group | Role | What they receive |
|---|---|---|
| Beneforte broccoli | Active comparator | Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet. Receives: Other: Beneforte broccoli |
| Parthenon broccoli | Placebo comparator | Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet. Receives: Other: Parthenon Broccoli |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary outcome measure is to assess the change in CVD risk after a 12 week broccoli intervention by assessing the change in concentration of LDL-cholesterol on which the power calculation was based.
The LDL cholesterol concentration (mmol/L) will be measured before and after a 12 week intervention with broccoli, using a Instrumentation Laboratories kit for use on an ILAB auto analyser.
Measured: Baseline and 12 weeks
Secondary outcomes (1)
To assess the effects of the broccoli intervention clinical biomarkers of CVD. The effect of the intervention on arterial stiffness will also be measured on a sub section of the total cohort (measurements carried out on the Reading cohort).
The clinical biomarkers include, hs-CRP (mg/L), NEFAs(mg/dL), Plasma NO(umol/L), hs-IL6(pg/mL), TNF-α(pg/mL), ox LDL(umol/L), IL-1beta(pg/L), PCOOH(pmols/L), F-2 isoprostanes (mg/mL/mg creatine) and 8-OHdG (ng/mL).
The effect of the intervention on arterial stiffness on a sub section of the cohort (Reading cohort)will also be measured. The first measurement will be Pulse wave velocity (m/sec); the 2nd measurement will be Laser Doppler Imaging with iontophoresis (perfusion units(area under the blood flow.time curve)).
Measured: Baseline and 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2013 (estimated)
- Study startJul 2012
- Primary completionMay 2014
- Study completionMay 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 95 participants (actual)
Sponsor and investigators
- Lead sponsor
- Quadram Institute Bioscience
- Sponsor type
- University, hospital or other
- Collaborators
- Biotechnology and Biological Sciences Research Council, Technology Strategy Board, United Kingdom, Monsanto Company, LLC, University of Reading
- Responsible party
- Sponsor
- Investigators
- Richard Mithen, Professor, Study director, Quadram Institute Bioscience
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01929564
- Sponsor's protocol ID
- IFR01/2012
- Acronym
- BASH
- Status last verified
- Jul 2014
- First submitted
- 27 Mar 2013
- Last updated
- 29 Jul 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Broccoli and Vascular Health Study
- ClinicalTrials.gov ID
- NCT01929564
- Acronym / sponsor ID
- BASH / IFR01/2012
- Conditions
- Cardiovascular Diseases
- Keywords
- cardiovascular disease, risk factor, broccoli, GST, blood pressure, Total cholesterol
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 95 participants (actual)
- Lead sponsor
- Quadram Institute BioscienceUniversity, hospital or other
- Collaborators
- Biotechnology and Biological Sciences Research Council, Technology Strategy Board, United Kingdom, Monsanto Company, LLC, University of Reading
- Study start
- Jul 2012
- Primary completion
- May 2014 (actual)
- Study completion
- May 2014 (actual)
- First posted
- 28 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The participants of this study will be men \& women ≥50 years who are deemed to have a 10-30% risk of developing CVD over the next 10 years. Their risk will be calculated using the Joint British Societies 2 (JBS2) guidelines on the prevention of CVD in clinical practise algorithm. This takes into account the participants age, sex, cholesterol values, blood pressure,family history and their ethnicity (SE Asian or not). The participants will be randomly assigned to one of two groups with the aid of a computer program called "minim" which uses their age, sex, BMI and smoking status to determine which broccoli each participant will consume on the intervention.
Each participant will consume 4 x 100g of their assigned broccoli, each week for 12 weeks on top of their normal diet. They will be allowed to eat the broccoli whenever they want during the week, but will be asked to note down when they eat it. A steamer will be provided so participants can cook their broccoli for the required 4-5 minutes. Participants will be asked to keep two diet diaries during their time on the intervention, one before they start the intervention and one towards the end. Blood samples and urine will also be collected, pre and post intervention, for the analysis of biomarkers of CVD.
This is joint project based at two sites, the Institute of Food (IFR) Research in Norwich and the University of Reading(UoR), in Reading. Samples from the participants at both sites will be analysed at IFR, UoR and companies in the United States.
Detailed description
This intervention will take place at two independent sites, The Institute of Food Research's Human Nutrition Unit (HNU)in Norwich and the Hugh Sinclair Human Nutrition Unit (HSU), at the University of Reading. The participants recruited from Norwich and Reading will solely attend the unit in their area and the paper work has been written to reflect this i.e.separate participant information sheets (PIS). In addition to the tests carried out at both sites, the Reading cohort will also undergo additional vascular tests, also reflected in the PIS. Despite the sites being independent, 96 participants will be recruited across both sites, with the possibility of uneven numbers from each site making up the final number.
The purpose of this study is to assess whether diet can affect an individuals chances of developing CVD, as it is one of the biggest killers in the UK. We are particularly interested in participants who have a 10%-30% risk of developing CVD. We are able to assess a person's risk with the help of the Joint British Societies 2 guidelines on the prevention of cardiovascular disease, cardiovascular disease risk prediction chart. These charts take a number of parameters we obtain from the participant, their age, sex, total cholesterol concentration, systolic blood pressure (BP), body mass index (BMI), serum high density lipoprotein concentration, their smoking status and diabetes status and put them into an algorithm. The result is a risk score out of 100, of a person developing CVD over the next 10 years.
The study will be conducted over two sites, Reading and Norwich, with a principal investigator assigned to each site. The total number of participants recruited over both sites will be 96. It may be that uneven numbers are recruited over the two sites e.g. 46 at one and 50 at another however regardless of the number at each site, 48 participants will be assigned to each of the two groups. One group will consume 400g of the commercially available high glucosinolate Beneforté® broccoli each week for 12 weeks and the other will consume 400g of a standard broccoli, Parthenon for 12 weeks.
As we are assessing the effect of diet on CVD risk, our participants will be screened initially. Their urine will be tested (urine dipstick test), their height, weight, waist and hip measurements, BMI, BP will be measured and questions linked to lifestyle choices (alcohol consumption, smoking status and physical activity) will be asked. A separate section pertaining to women's health will also be present on the questionnaire.
All participants will be asked to give written informed consent before they can participate in the intervention study. The Reading cohort will be sent a copy of the consent and medical declaration forms to read through at home. The forms sent to the homes will be clearly distinguishable from the real forms as they will have the watermark with "SAMPLE" written across them.
CVD risk assessment calculator This calculator will be used once the results of the screening are known. A program devised by the University of Manchester will be used to calculate the risk our participants have of developing CVD over the next 10 years. This program is based on the Joint British Societies 2 guidelines on the prevention of CVD risk prediction charts. For the purposes of this study we would like our participants to fall into the 10%-30% risk category as most literature suggests people in this range may benefit from dietary change, without the need for medication, in the most part. The CVD risk scores will be sent to the participants GP and we will continue to advise our participants to discuss the results with their GPs if they score >10%.
Genotyping There is evidence to suggest that a person's genetic make-up may affect the way isothiocyanates (ITCs), one of the active components of broccoli, work. Of the 30,000 genes found in humans a group of genes associated with the protein glutathione S-transferase M1 (GSTM1) has been shown to affect ITCs after consumption and has been implicated in CVD. There is evidence to suggest that individuals with a deletion in GSTM1 breakdown the glucosinolate, from which the ITC sulforaphane is derived, differently to individuals that have the gene. We also know that glutathione S-transferase theta-1 (GSTT1) may also be involved in reducing the likelihood of developing CVD.
Along with the GST gene family and their association with cruciferous vegetables, there are a number of other genes that have been implicated in CVD itself. These include genes associated with lipid metabolism, thrombosis, leukocyte adhesion and nitric oxide production and thus blood vessel dilation. This is by no means an exhaustive list and will therefore remain open to other viable candidates.
Vascular measurements As we age, our arteries stiffen which causes an increase in the demands of the heart and an increase in blood pressure. This increase in BP can dramatically increase the risk of heart attack, stroke and heart failure. Arterial stiffness has also been associated with many of the common risk factors associated with CVD such as age, high blood pressure, smoking, cholesterol levels and obesity, but importantly, arterial stiffness has been shown to be an independent predictor of CVD in a large section of society.
There are many ways in which arterial stiffness can be assessed. We will be looking at blood pressure, which will be very familiar to most participants in our age range (over 50yrs of age). The only difference being that the participant will wear a cuff for an hour and readings will be collected every ten minutes.
Another method will be Pulse Wave Analysis (PWA), where a probe will be held against the neck and the upper thigh to take the measurements for up to a minute at a time. As participants may not be wholly familiar with this technique, it is hoped that a short video clip could be shown on a laptop or diagrams/photographs of the technique will be discussed with the participant at screening.
Restricted conditions prior to study day Before the study day the participants will be asked to abstain from a number of activities. This will be clearly stated in the PIS.
These include:
- No alcohol or caffeine for 24 hours before the study day. Participants who consume a lot of caffeine will be advised that they may suffer from headaches. They will be asked to tell the study scientist if they needed to take any medication as a consequence.
- Low fat meal to be consumed the night before the study day. Participants will be asked to eat a low fat meal from a selected list that we give them. We will ask that the meal is consumed before 10pm, as the participants will then have to fast for their study day.
- Fasting for at least 8 hours. Participants will need to fast for at least 8 hours. This means that they won't be able to eat or drink anything, apart from water during this time. They can drink as much water as they feel they need.
- No heavy exercise the morning of their study day. Participants will be asked not to engage in any vigorous exercise the morning of their study day. This will be defined as any activity that causes an increase in heart rate, panting and/or sweating. A participant who normally cycles will be asked not to on the morning of their study day.
- No smoking an hour before their study day measurements. All participants that smoke will be asked to abstain from smoking at least an hour before their study day. We would also ask that they avoid all passive smoking.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Beneforte broccoli | Active comparator | Other: Beneforte broccoliFour x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet. |
| Parthenon broccoli | Placebo comparator | Other: Parthenon BroccoliFour x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Men and women aged ≥ 50 years will be recruited onto the study using the JBS 2 cardiac risk assessor calculator.
- Scores of 10%-30% will be acceptable for participation in the study.
Key exclusion criteria (35 listed)
- Those unable to give written informed consent
- Those unwilling to provide GP details
- Those already consuming Beneforté ® broccoli, unless they are willing to discontinue consumption for 8 weeks prior to starting the study.
- Diagnosed diabetics
- Fasting glucose >7mmol/L (WHO guidelines for diabetics)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beneforte broccoliFour x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet | Other | Beneforte broccoli |
| Parthenon BroccoliFour x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet | Other | Parthenon broccoli |
Primary outcome
The primary outcome measure is to assess the change in CVD risk after a 12 week broccoli intervention by assessing the change in concentration of LDL-cholesterol on which the power calculation was based.
Time frame: Baseline and 12 weeks
The LDL cholesterol concentration (mmol/L) will be measured before and after a 12 week intervention with broccoli, using a Instrumentation Laboratories kit for use on an ILAB auto analyser.
1 secondary outcome
To assess the effects of the broccoli intervention clinical biomarkers of CVD. The effect of the intervention on arterial stiffness will also be measured on a sub section of the total cohort (measurements carried out on the Reading cohort).
Time frame: Baseline and 12 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2014.
Related trials for Cardiovascular Diseases
RecruitingObservational study
Genetics of Type 2 Diabetes in West Africans
Hypertension, Diabetes
RecruitingObservational study
Atrial Fibrillation Patients Treated With Catheter Ablation
Atrial Fibrillation, Atrial Fibrillation Recurrent
RecruitingPhase 1
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
AML, Multiple Myeloma
Active, not recruiting
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Primary Aldosteronism, Resistant Hypertension
RecruitingPhase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Mithen, Professor study director
Quadram Institute Bioscience
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Beneforte broccoli and Parthenon Broccoli in people with Cardiovascular Diseases, run by Quadram Institute Bioscience at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary outcome measure is to assess the change in CVD risk after a 12 week broccoli intervention by assessing the change in concentration of LDL-cholesterol on which the power calculation was based. (time frame: Baseline and 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2014.